Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ormat Technologies, Inc. (ORA): Are Hedge Funds Right About This Stock?

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile gigantic failures like hedge funds’ recent losses in Valeant. Let’s take a closer look at what the funds we track think about Ormat Technologies, Inc. (NYSE:ORA) in this article.

Is Ormat Technologies, Inc. (NYSE:ORA) a splendid stock to buy now? The smart money is in a pessimistic mood. The number of long hedge fund positions fell by 5 lately. The trading environment surrounding Ormat Technologies, Inc. (NYSE:ORA) took a similar turn, with its stock losing 9.69% value throughout the quarter. Such a response prompted us to find more about the hedge fund behavior by covering the ones that held stakes in Ormat Technologies, Inc. (NYSE:ORA) at the end of the third quarter.

To find out hedge funds’ opinion about companies with similar market caps, we will also compare Ormat Technologies, Inc. (NYSE:ORA) to other stocks, including Liberty Tripadvisor Holdings Inc (NASDAQ:LTRPA), Amicus Therapeutics, Inc. (NASDAQ:FOLD), and Abengoa Yield PLC (NASDAQ:ABY) to get a better sense of its popularity.

Follow Ormat Technologies Inc. (NYSE:ORA)
Trade (NYSE:ORA) Now!

Today, there are a multitude of methods investors employ to evaluate publicly traded companies. Some of the less known methods are hedge fund and insider trading sentiment. Our researchers have shown that, historically, those who follow the top picks of the elite money managers can beat the broader indices by a solid margin (see the details here).

With all of this in mind, we’re going to check out the fresh action regarding Ormat Technologies, Inc. (NYSE:ORA).

How have hedgies been trading Ormat Technologies, Inc. (NYSE:ORA)?

At the end of Q3, a total of 7 of the hedge funds tracked by Insider Monkey were bullish on this stock, a decrease of 42% from the second quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists an “upper tier” of key hedge fund managers who were increasing their stakes considerably (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Ian Simm’s Impax Asset Management has the largest position in Ormat Technologies, Inc. (NYSE:ORA), worth close to $11.8 million, comprising 0.8% of its total 13F portfolio. Coming in second is Renaissance Technologies, holding a $7.8 million position; the fund has less than 0.1% of its 13F portfolio invested in the stock. Remaining professional money managers that are bullish encompass Mario Gabelli’s GAMCO Investors, Bernard Lambilliotte’s Ecofin Ltd and D E Shaw.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.